|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sections from formalin-fixed paraffin-embedded tumor blocks from 52 neuroblastoma cases (17 with localized, 35 with advanced disease) were subjected to immunohistochemistry for P-gp and GST-pi expressions.
|
12078865 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The GST-tag present in the fusion protein, by itself, was found to undergo significant phosphorylation by tumor cell extracts and contribute to spurious results.
|
12430183 |
2002 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We wished to evaluate whether variant allelic forms of GST isoenzymes were associated with an increased susceptibility for brain tumors and age of tumor onset.
|
12241105 |
2002 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A significant correlation was observed between null GST-Ml genotype and p53 overall mutations (p=0.0003), K-ras mutations (p=0.02), non peripheral tumors (p=0.04) and smoking habits (p=0.002).
|
11848510 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The GST enzyme activities in tumours were independent of tumour stage, or the age and gender of the patients.
|
11218045 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The relationship of MDR1 and GST-pi with the tumour marker CEA implies that evaluation of CEA can help in discriminating between tumours with high or low expression of drug resistance.
|
11326685 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the role of hsp27 expression was studied in vivo by immunochemistry in 98 patients with head and neck squamous cell carcinoma treated by radiotherapy. hsp27 was correlated with local control of the tumor and with clinical and biologic factors potentially able to affect the local control, including p53, ki-67, ploidy, and GST.
|
10725639 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Glutathione S-transferase (GST) M1 polymorphism is a marker for susceptibility to smoking-related neoplasms, such as lung and bladder cancer.
|
10616169 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, there was no significant correlation between GST-% mRNA overexpression and clinical stage, T stage (tumor size), N stage (neck nodal status), pathological nodes, or patient survival.
|
9815545 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data indicate that high GST-pi expression in tumor cells and the presence of the GST-pi protein in tumor cell nuclei are associated with clinically more aggressive gliomas and are strong predictors of poor patient survival.
|
9815622 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GPx was positively correlated with GST (r = 0.3, P = 0.0048) and with GSH (r = 0.5, P = 0.0001) in tumor as well as in normal tissue.
|
9209662 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
After surgery alone, the risk of local recurrence at 6 years was higher for patients with tumors exhibiting elevated levels of p53 and GST-pi protein expression than for patients with low levels (hazard ratio [HR] = 3.1, 95% confidence interval [CI] = 1.3-7.7, two-sided P = .012; HR = 2.7, 95% CI = 1.1-6.4, two-sided P = .026, respectively).
|
9150188 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have suggested that glutathione S-transferase pi (GST-pi) may play a role in determining tumor sensitivities to cytotoxic drugs.
|
8551660 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of the detoxication enzyme glutathione transferase P1-1 (GST P1-1) at elevated levels has been noted in many types of human tumors, including melanomas.
|
7576742 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this patient, anticancer drugs were determined by measurements of mRNA expression of chemoresistance-related genes, such as O6-methylguanine-DNA methyltransferase (MGMT), mdr1, glutathione S-transferase (GST)-pi, and metallothionein (MT) in the resected tumor.
|
8629231 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically detected GST-pi-positive tumors were noted in 35 of 62 excised tumors.
|
8055443 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Particular glutathione S-transferase (GST) isoenzymes differ in their substrate specificity, however, and their presence or absence might therefore account for the resistance of tumours to particular chemotherapeutic drugs, as already established for cultured cell lines.
|
7818489 |
1994 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The response of SCLC to chemotherapy was examined in terms of (a) patient survival, (b) drug sensitivity of tumors in patients and of tumor xenografts in nude mice, and (c) expression of multidrug resistance gene MDR1 and GST-pi gene.
|
7902445 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Relative GST-pi expression (tumor/mucosa) ranged from 0.31 to 1.52 (0.821 +/- 0.40: mean +/- SD), and only 6 out of 17 cases demonstrated increased GST-pi transcripts in tumor tissue over normal tissue.
|
8517648 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant tumor response to ADR was observed in two esophageal xenograft tumors of six tumor lines, and one gastric tumor partially responded to ADR. mRNA expression of the MDR1 and GST-pi genes was elevated in five tumor lines including three ADR responsive tumors, whereas mRNA expression of the topoisomerase II gene was detected in all six tested tumor lines.
|
1314532 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lack of staining of tumour epithelium for GST pi was significantly associated with poorer tumour differentiation (higher grade).
|
1347080 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A series of 36 HSTS, 24 untreated and 12 homogeneously treated with a presurgical chemotherapeutic regimen consisting of doxorubicin (intra-arterial) and iphosphamide (intra-vein), was analyzed for expression of MDR1 and the glutathione-S-transferase-pi (GST-pi) gene in order to identify molecular phenomena which may be implicated in the chemoresistance displayed by these tumors.
|
1606072 |
1992 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MDR1 and GST-pi expression, which is known to be a marker for adriamycin resistance, was detected in six (66.7%) and seven (77.8%) of the nine clinically resistant tumors, respectively.
|
1850221 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Coamplification of GST pi, HSTF1 and INT2 was observed in five tumors, and coamplification of GST pi and HSTF1 without amplification of INT2 in another tumor.
|
1826346 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mean GST-pi mRNA value in the tumor tissues (n = 25) was significantly (P less than 0.01) elevated as compared with that in background mucosa (n = 29), and in ten of 25 tumors (40%) the level of GST-pi mRNA exceeded the mean normal tissue value by two standard deviations (normal mean value + 2 X SD).
|
2015556 |
1991 |